tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GILD Stock Latest News

Gilead Sciences’ New Study on Sacituzumab Govitecan: Market Implications and Study Insights
Company AnnouncementsGilead Sciences’ New Study on Sacituzumab Govitecan: Market Implications and Study Insights
17h ago
GILD
Gilead Sciences Advances Ulcerative Colitis Treatment with GS-1427 Study
PremiumCompany Announcements
Gilead Sciences Advances Ulcerative Colitis Treatment with GS-1427 Study
2d ago
GILD
Gilead Sciences Advances in Triple-Negative Breast Cancer Treatment
PremiumCompany Announcements
Gilead Sciences Advances in Triple-Negative Breast Cancer Treatment
3d ago
GILD
Gilead Sciences and Arcus Biosciences: New Lung Cancer Treatment Combinations Under Evaluation
PremiumCompany Announcements
Gilead Sciences and Arcus Biosciences: New Lung Cancer Treatment Combinations Under Evaluation
5d ago
GILD
RCUS
Gilead presents new data on twice-yearly lenacapavir for HIV prevention
PremiumThe Fly
Gilead presents new data on twice-yearly lenacapavir for HIV prevention
5d ago
GILD
Gilead price target raised to $114 from $105 at Leerink
PremiumThe FlyGilead price target raised to $114 from $105 at Leerink
5d ago
GILD
Gilead estimates Q2 acquired IPR&D expenses of $61M
Premium
The Fly
Gilead estimates Q2 acquired IPR&D expenses of $61M
8d ago
GILD
KYMR
Gilead Sciences’ Phase 3 Study: A New Hope for HIV-1 Treatment?
Premium
Company Announcements
Gilead Sciences’ Phase 3 Study: A New Hope for HIV-1 Treatment?
8d ago
GILD
Gilead Sciences Advances HIV Prevention with Lenacapavir Study
PremiumCompany Announcements
Gilead Sciences Advances HIV Prevention with Lenacapavir Study
9d ago
GILD
Gilead Sciences’ New HIV Treatment Study: A Potential Game Changer?
PremiumCompany Announcements
Gilead Sciences’ New HIV Treatment Study: A Potential Game Changer?
9d ago
GILD
Gilead to supply lenacapavir to Global Fund for up to 2M people
PremiumThe Fly
Gilead to supply lenacapavir to Global Fund for up to 2M people
10d ago
GILD
Positive Outlook for Gilead Sciences Driven by Yeztugo’s Market Potential and FDA Approval
PremiumRatings
Positive Outlook for Gilead Sciences Driven by Yeztugo’s Market Potential and FDA Approval
10d ago
GILD
Gilead Sciences Advances in Solid Tumor Treatment: A Phase II Study Update
PremiumCompany AnnouncementsGilead Sciences Advances in Solid Tumor Treatment: A Phase II Study Update
15d ago
GILD
Gilead Sciences’ Ongoing Study on TAF for Pediatric Hepatitis B: Market Implications
Premium
Company Announcements
Gilead Sciences’ Ongoing Study on TAF for Pediatric Hepatitis B: Market Implications
15d ago
GILD
Gilead Sciences Completes Long-Term Study on Filgotinib for Rheumatoid Arthritis
Premium
Company Announcements
Gilead Sciences Completes Long-Term Study on Filgotinib for Rheumatoid Arthritis
16d ago
GILD
Kymera Therapeutics assumed with an Overweight at Morgan Stanley
PremiumThe Fly
Kymera Therapeutics assumed with an Overweight at Morgan Stanley
16d ago
SNY
GILD
Gilead Sciences’ Promising Phase II Study on Sacituzumab Govitecan for Solid Tumors
PremiumCompany Announcements
Gilead Sciences’ Promising Phase II Study on Sacituzumab Govitecan for Solid Tumors
17d ago
GILD
Gilead Sciences Advances Pediatric Hepatitis B Treatment with Ongoing Study
PremiumCompany Announcements
Gilead Sciences Advances Pediatric Hepatitis B Treatment with Ongoing Study
17d ago
GILD
Gilead and Arcus Biosciences’ Promising Oncology Study Update
PremiumCompany Announcements
Gilead and Arcus Biosciences’ Promising Oncology Study Update
19d ago
GILD
RCUS
Supreme Court decision win for Gilead, says Wells Fargo
PremiumThe FlySupreme Court decision win for Gilead, says Wells Fargo
20d ago
GILD
USPSTF ruling a favorable outcome for Gilead, says Morgan Stanley
Premium
The Fly
USPSTF ruling a favorable outcome for Gilead, says Morgan Stanley
22d ago
GILD
Gilead Sciences’ Promising Phase 3 Study on Triple Negative Breast Cancer
Premium
Company Announcements
Gilead Sciences’ Promising Phase 3 Study on Triple Negative Breast Cancer
22d ago
GILD

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >